Nigeria’s pharmaceutical sector is at a crossroads, facing significant challenges but also harboring immense potential for growth and transformation. The 2025 Nigeria Pharmaceutical Industry Growth and Investment Summit brought together key stakeholders, including industry leaders, investors, and government officials, to address the urgent need to enhance local pharmaceutical manufacturing capacity. The consensus among participants was clear: strategic investments, technological advancements, and collaborative efforts are essential to achieving sustainable growth and self-sufficiency in pharmaceutical production. A central concern highlighted was the country’s overreliance on imported medicines, making the healthcare system vulnerable to external factors like currency fluctuations and supply chain disruptions.
A recurring theme throughout the summit was the imperative for scalable structures within the pharmaceutical industry. Former President of the Pharmaceutical Society of Nigeria, Ahmed Yakasai, emphasized the need for robust financial models and strategic mergers to enable companies to expand their operations and delve into more complex pharmaceutical manufacturing, including vaccine production and injectables. He envisioned Nigeria as a pharmaceutical hub not only for the ECOWAS region but for the entire African continent, leveraging the African Continental Free Trade Agreement to expand market reach. This ambitious vision necessitates a significant shift from the current focus on simple formulations to encompass a broader range of pharmaceutical products.
Echoing the call for domestic solutions, Sammy Ogunjimi, CEO of Codix Group, lamented the comparatively slow growth of the pharmaceutical sector compared to other industries like telecommunications and oil and gas. He underscored the crucial role of local investment in driving innovation and technology transfer, emphasizing that homegrown solutions are the most sustainable way to address the country’s pharmaceutical needs. Ogunjimi urged local entrepreneurs to take ownership of the challenge and invest in building local capacity, reducing reliance on foreign companies. This sentiment reflects a growing recognition that sustainable growth requires empowering local players to take the lead in developing the pharmaceutical sector.
Ayodeji Alaran, CEO of PBR Life Sciences, reinforced the urgency of the situation, pointing out that Nigeria currently imports 70% of its consumed medicines. He emphasized the significant opportunity presented by Nigeria’s burgeoning population and the projected growth of the pharmaceutical market, urging the private sector to take the lead in investing in local production. Alaran framed the decision to invest in local capacity as a necessity rather than a choice, arguing that building resilient domestic manufacturing is essential for securing access to affordable medicines and fostering economic growth. His call to action centered on the belief that the future of Nigerian healthcare hinges on the investment decisions made today.
Dr. Abdu Mukhtar, National Coordinator of the Presidential ‘Unlocking Healthcare Value-Chain’ Initiative, presented a compelling economic case for investing in the healthcare sector. He highlighted the significant growth potential of the sector, citing the disparity between Nigeria’s current healthcare contribution to GDP (3-4%) and that of developed nations like the US (17-18%). Mukhtar argued that investing in healthcare, particularly pharmaceuticals, presents a lucrative opportunity for investors while simultaneously contributing to national economic growth and diversification. He projected a doubling of the life sciences sector in Nigeria by 2030, further underscoring the attractive investment prospects.
To further incentivize local production, Dr. Mukhtar outlined government initiatives aimed at creating a more conducive environment for manufacturers. These include the implementation of zero import duty and zero VAT on equipment and raw materials for local pharmaceutical production, a measure instituted through a Presidential Executive Order signed by President Bola Tinubu. Additionally, the newly established Medipool, a purchasing organization, is designed to provide a stable market for locally manufactured pharmaceuticals through aggregated procurement and long-term contracts. These initiatives aim to provide manufacturers with the assurance of demand, encouraging investment and expansion of local production. Dr. Mukhtar expressed optimism about the potential of these initiatives, setting a target of 70% local production of healthcare products by 2030. This ambitious goal reflects a commitment to transforming Nigeria’s pharmaceutical landscape and ensuring access to essential medicines for its growing population.
